The Knowledge, Opinions, Attitudes of Physicians About Biosimilar Drugs: A University Hospital Data

Year 2022, , 650 - 658, 31.05.2022

Ebru Gökdemir Seyma Oncu Ayse Gelal Reyhan Uçku , Aylin Arici

https://doi.org/10.30621/jbachs.948898

Cited By: 1

Abstract

Purpose: To evaluate the knowledge, opinions and prescribing attitudes of physicians working in an university hospital about biosimilar drugs and analyse the factors affect these parameters.

Methods: In this descriptive, cross-sectional study, data was collected using a questionnaire consisting of 5 sections and 41 questions evaluating the knowledge, opinions and prescribing attitudes of physicians about biosimilar drugs. Descriptive statistics was used to report the findings; relationship between dependent and independent variables were examined using the t-test for parametric data, and Mann Whitney U and Kruskall Wallis analysis for nonparametric data. P <0.05 was considered statistically significant.

Results: Questionnaire response rate was 61.9% (n=114). Physicians mean knowledge score about biosimilar drugs was 7.6 ± 2.5 out of 14 points. Have heard the concept the biosimilar drug, had training towards biosimilar drugs and high academic level were increased the mean knowledge score. Of the respondents, 45.2% of the physicians stated that biosimilar drugs are not as effective as biological reference drugs, and 35.9% thought that they aren’t safe. More than half of the physicians (56.6%) stated that they did not hesitate to prescribe biosimilar drugs.

Conclusions: Physicians' general knowledge level on biosimilar drugs was low and they had doubts about the efficacy and safety of biosimilar drugs. This might be related with lack of knowledge. Therefore structured training programmes related in this area, might increase the knowledge level and might positively affect physicians' opinions and attitudes on biosimilar drugs

Keywords

Biosimilar drug, level of knowledge, opinion, attitude, pyhsicians

References

• 1. Kang HN, Knezevic I. Regulatory evaluation of biosimilars throughout their product life-cycle. Bull World Health Organ. 2018;96(4):281–5.
• 2. Blandizzi C, Meroni PL, Lapadula G. Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues. Clin Ther [Internet]. 2017;39(5):1026–39.
• 3. Uhlig T, Goll GL. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford). 2017;56(4):iv49–62.
• 4. Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: A systematic review. J Manag Care Spec Pharm. 2019;25(1):102–12.
• 5. Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2017;33(12):2160–72.
• 6. Chapman SR, Fitzpatrick RW, Aladul MI. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: Result of a UK web-based survey. BMJ Open. 2017;7(6):1–8.
• 7. Karateev D, Belokoneva N. Evaluation of physicians’ knowledge and attitudes towards biosimilars in Russia and issues associated with their prescribing. Biomolecules. 2019;9(2).
• 8. Micó-Pérez RM, Payares-Herrera C, Palomo-Jiménez PI, Sánchez-Fierro J, Avendaño-Solá C L-CJ. Knowledge about Biosimilars in Primary Care: a study by the Spanish Society of Primary Care Physicians. Semergen. 2018;6(44):380–8.
• 9. O’Callaghan J, Bermingham M, Leonard M, Hallinan F, Morris JM, Moore U, et al. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland. Regul Toxicol Pharmacol. 2017;88:252–61.
• 10. Choudhury S, Pradhan R, Dubey L, Barman L, Biswas T, Das M, et al. Knowledge and perception regarding clinical trials among doctors of government medical colleges: A questionnaire-based study. Perspect Clin Res. 2016;7(2):94.
• 11. Al-Tannir MA, Alkatan HM, Al-Badr AH, Al-Tannir MM, Abu-Shaheen AK. Knowledge, attitudes, practices and perceptions of clinicians towards conducting clinical trials in an Academic Tertiary Care Center. Saudi Med J. 2018;39(2):191–6.
• 12. Pasina L, Casadei G, Nobili A. A survey among hospital specialists and pharmacists about biosimilars. Eur J Intern Med. 2016;35:e31–3.
• 13. Hadoussa S, Bouhlel M, Soussi MA, Drira C, Hadoussa M, Khrouf MR. Perception of hematologists and oncologists about the biosimilars: A prospective Tunisian study based on a survey. J Oncol Pharm Pract. 2020;26(1):124–32.
• 14. Beck M, Michel B, Rybarczyk-Vigouret MC, Levêque D, Sordet C, Sibilia J, et al. Rheumatologists’ Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey. BioDrugs. 2016;30(6):585–92.
• 15. Haustein R. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J. 2012;1(3):120–6.
• 16. Dutta B, Huys I, Vulto AG, Simoens S. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! BioDrugs [Internet]. 2020;34(2):159–70.
• 17. Cook JW, McGrath MK, Dixon MD, Switchenko JM, Harvey RD, Pentz RD. Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing. Ther Adv Med Oncol. 2019;11:1–12.
• 18. Aladul MI, Fitzpatrick RW, Chapman SR. Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: A qualitative study. BMJ Open. 2018;8(11):1–8.
• 19. Reinisch W, Smolen J. Biosimilar safety factors in clinical practice. Semin Arthritis Rheum [Internet]. 2015;44(6):S9–15.
• 20. Grabowski D, Henderson B, Lam D, Keystone EC, Thorne C, Jamal S, et al. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. Clin Rheumatol. 2015;34(8):1427–33.
• 21. Kellner H, Domènech E, Lakatos PL, Marsal J, Agboton C, Cassese M, et al. AB0314 Awareness and Acceptance of Biosimilars by Rheumatologists in Eleven Eu Countries. Ann Rheum Dis. 2016;75(Suppl 2):1008.1-1008.
• 22. Hallersten A, Fürst W, Mezzasalma R. Physicians prefer greater detail in the biosimilar label (SmPC) - Results of a survey across seven European countries. Regul Toxicol Pharmacol [Internet]. 2016;77:275–81.
• 23. Fabiani C, Vitale A, Emmi G, Sgheri A, Lopalco G, Sota J, et al. The role of biosimilars in uveitis: Long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors. Front Pharmacol. 2019;10(December).
• 24. Puig L L-FA. Biosimilars for the treatment of psoriasis. Expert Opin Biol Ther. 2019;19(10):993–1000.